Former J&J Senior Scientific Director and immunology expert joins at a pivotal time. Touchlight driving its dbDNA technology towards clinical development in therapeutic and prophylactic vaccines
28 April, 2020
To mark the 30th Anniversary of World Haemophilia Day, Sobi have released the 2020 Haemophilia Index which examines the quality of life for people with haemophilia in Europe, including the UK and the reach of humanitarian aid across the globe.
26 April, 2020
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.
25 April, 2020
Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments for this advanced prostate cancer population with high unmet needs
24 April, 2020
Amsterdam (The Netherlands) and Niel (Belgium) April 22, 2020 Frame Therapeutics, a new biotechnology company focused on the development of neoantigen-based cancer vaccines, today announced that they have forged a research collaboration with eTheRNA immunotherapies NV, a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform.
23 April, 2020
Looking for new ways to test your knowledge during the lockdown? Leading global supplier of research materials, Goodfellow, has recently updated its Mr. Material game, a free educational app which tests the extent of your periodic table knowledge.
22 April, 2020
Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.
22 April, 2020
Construction of the UK’s New Vaccines Centre by Glencar Construction Starts Well Ahead of Schedule as Timelines are Fast Tracked Due to Covid-19
22 April, 2020
Nottingham-based leading independent DMPK provider, XenoGesis, has been awarded the prestigious Queen’s Award for Enterprise, International Trade, in recognition of its outstanding year-on-year export growth.
22 April, 2020
Panthera’s second clinical trial site in the UK, in North Manchester is open for business.As a standalone site ideal for existing or new trials with much lower contamination risk during COVID-19
21 April, 2020
Freshly isolated human chondrocytes exhibit a natural, biologically relevant phenotype during in vitro expansion
15 April, 2020
Last week the Government announced the establishment of large scale national COVID-19 hub laboratories across the UK. The initial laboratories have been established in Cheshire, Milton Keynes and Glasgow.
08 April, 2020
6th April 2020, Alderley Park: Catapult Ventures has announced the appointment of Vijay Curthan as Investment Director in its GM & Cheshire Life Sciences Fund. Vijay joins Catapult with a background in healthcare private equity, investment banking and pharma industry corporate strategy
08 April, 2020
Behavioural data of 26,700 health app users generates heat map of staying home/going-out population across all local authorities
08 April, 2020
New arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system. First in the market, this unique service complements the Company’s T cell screening service
07 April, 2020
OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak
07 April, 2020